Genetic Susceptibility to Kidney Cancer
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00854022 |
Recruitment Status :
Terminated
(Funding ended)
First Posted : March 2, 2009
Last Update Posted : February 25, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Renal Cell Carcinoma |
Study Type : | Observational |
Actual Enrollment : | 6 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Genetic Susceptibility to Renal Cell Carcinoma |
Study Start Date : | July 2008 |
Actual Primary Completion Date : | March 2013 |
Actual Study Completion Date : | March 2013 |

Group/Cohort |
---|
Healthy
Healthy adults, of any ethnicity, or sex, and with no previous history of cancer, except for non-melanoma skin cancer
|
RCC
Adult patients with newly diagnosed (diagnosed within the year of enrollment) renal carcinoma (RCC) any ethnicity, or sex, who have not received prior chemotherapy or radiotherapy.
|
- To identify interindividual differences in inherited genetic instability [ Time Frame: 12 months ]
Biospecimen Retention: Samples With DNA
We will utilize the blood collected to run several laboratory analyses that will assess DNA damage/repair, telomere length, telomerase activity, and other genetic instability as predictors of RCC risk. All information linking this unique identifier to the participant will be kept in a secure location under lock-and-key password protected.
In addition, RCC tumor and adjacent normal tissue samples may be obtained from the MDACC Institutional Tissue Bank (ITB) for cases only. The samples obtained will be left over from surgical procedures, so as to prevent any additional distress to the patient.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- Adult patients of any ethnicity or sex, who have a been diagnosed with possible Renal Cell Carcinoma within the past year.
Exclusion Criteria:
- Must not have received chemotherapy, biological therapy or radiation therapy in the 6 months preceding enrollment will
- Must not have had RCC, or metastatic RCC,
- Must not have had a renal transplantation

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00854022
United States, Texas | |
MD Anderson Cancer Center | |
Houston, Texas, United States, 77030 |
Principal Investigator: | Seth P. Lerner, MD | Baylor College of Medicine |
Responsible Party: | Seth Lerner, Professor, Baylor College of Medicine |
ClinicalTrials.gov Identifier: | NCT00854022 |
Other Study ID Numbers: |
H-17150 |
First Posted: | March 2, 2009 Key Record Dates |
Last Update Posted: | February 25, 2020 |
Last Verified: | February 2020 |
Carcinoma Carcinoma, Renal Cell Genetic Predisposition to Disease Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Adenocarcinoma Kidney Neoplasms |
Urologic Neoplasms Urogenital Neoplasms Neoplasms by Site Kidney Diseases Urologic Diseases Disease Susceptibility Disease Attributes Pathologic Processes |